Latest news
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeatMarketBeat · Sat, 08 Aug 2026 00:16:46 GMTSpyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeatMarketBeat · Fri, 07 Aug 2026 08:09:43 GMTSpyGlass Pharma 2Q 2026: Net loss $(19.9)M, EPS $(0.59) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 21:22:06 GMTSpyGlass Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 20:37:00 GMTSpyGlass Pharma Q2 net loss widens on higher expenses - TradingViewTradingView · Thu, 06 Aug 2026 20:21:35 GMTSpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewswireGlobeNewswire · Thu, 06 Aug 2026 20:05:00 GMTSpyGlass glaucoma trial enrollment remains on track for 2027 - Stock TitanStock Titan · Thu, 06 Aug 2026 20:05:00 GMTIf You're Not Paying for the Tokens... - spyglass.orgspyglass.org · Thu, 06 Aug 2026 16:24:41 GMT